Progressive supranuclear palsy (PSP) is a movement disorder with prominent tau neuropathology. Brain diseases with abnormal tau deposits are called tauopathies, the most common of which is
Alzheimer's disease. Environmental causes of tauopathies include repetitive head trauma associated with some sports. To identify common genetic variation contributing to risk for tauopathies, we carried out a genome-wide association study of 1,114 individuals with PSP (cases) and 3,247 controls (stage 1) followed by a second stage in which we genotyped 1,051 cases and 3,560 controls for the stage 1 SNPs that yielded P ≤ 10 −3 . We found significant previously unidentified signals (P < 5 × 10 −8 ) associated with PSP risk at STX6, EIF2AK3 and MOBP. We confirmed two independent variants in MAPT affecting risk for PSP, one of which influences MAPT brain expression. The genes implicated encode proteins for vesicle-membrane fusion at the Golgi-endosomal interface, for the endoplasmic reticulum unfolded protein response and for a myelin structural component. PSP is a rare neurodegenerative movement disorder clinically char acterized by falls, axial rigidity, vertical supranuclear gaze palsy, bradykinesia and cognitive decline. Though PSP is rare (with a prevalence of 3.1-6.5 per 100,000 people 1 ), after Parkinson's disease, PSP is the second most common cause of degenerative parkinsonism 2 . PSP is a tauopathy with abnormal accumulation of tau protein within neurons as neurofibrillary tangles, primarily in the basal ganglia, diencephalon and brainstem, with neuronal loss in the globus pallidus, subthalamic nucleus and substantia nigra. Abnormal tau also accumulates within oligodendroglia and astrocytes 3 . In Alzheimer's disease, even though all affected indivi duals have neurofibrillary tangles, Aβ plaques are closely tied to the primary disease process, and, thus, Alzheimer's disease is a sec ondary tauopathy. PSP is a primary tauopathy because tau is the major abnormal protein observed. Both environmental insults and inherited factors contribute to the risk of developing tauopathies 4 . Repetitive brain trauma, associated with certain sports, can cause Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy 7 0 0 VOLUME 43 | NUMBER 7 | JULY 2011 Nature GeNetics l e t t e r s chronic traumatic encephalopathy associated with tau deposits 5 . Viral encephalitis, associated with subsequent parkinsonism, is also associated with tau neuropathology. In PSP, neurotoxins 4 and low education levels 6 may also contribute to risk. Genetic risk for PSP is in part determined by variants at a 1Mb inversion poly morphism that contains a number of genes, including MAPT, the gene that encodes tau 7 . The inversion variants are called H1 and H2 'haplotypes' , with H1 conferring risk for PSP 8 . H1 also contributes to risk for corticobasal degeneration 9, 10 and Guam amyotrophic lateral sclerosis/parkinsonism dementia complex 11 , both of which are rare tauopathies. H1 does not contribute to risk for Alzheimer's disease. Notably, H1 is also a risk factor for Parkinson's disease 12 , a movement disorder with clinical features that overlap those of PSP, yet in Parkinson's disease there are no neuropathologically recognizable taucontaining lesions.
We performed a genome wide association study (GWAS) of PSP to identify genes that modify risk for this primary tauopathy. We performed a twostage analysis to maximize efficiency while maintain ing power 13, 14 . For stage 1, we used only autopsied cases (n = 1,114), thereby essentially eliminating incorrect diagnoses. These cases were contrasted with 3,287 controls; 96% of cases and 90% of controls were of European ancestry ( Table 1 and Supplementary Table 1) . We assessed association between genotypes at 531,451 SNPs and PSP status among subjects of all ancestries (Supplementary Table 2 ) and those of only European ancestry ( Table 2 and Supplementary  Fig. 1 ) using an additive model. Results from both ancestry groups were similar. Because our controls were younger than our cases, we compared the control allele frequencies at significant and strongly suggestive SNPs to those of older controls (N = 3,816) from three datasets from the US National Institutes of Health (NIH) repository Database for Genotypes and Phenotypes (Supplementary Table 3 ). Only SNPs with no significant differences in allele frequencies between old and young controls are presented in Table 2 .
Stage 1 P values (P 1 ) for SNPs in three regions crossed the signi ficance threshold of P < 5 × 10 −8 ( Table 2 and Fig. 1 ). At 1q25.3, a SNP in STX6 crossed this threshold (P 1 = 1.8 × 10 −9 ). Another SNP at 3p22.1 in MOBP crossed this threshold (P 1 = 1.0 × 10 −9 ). The third significant region was 17q21.31, in which 58 SNPs had P 1 < 5 × 10 −8 ( Table 2 and Fig. 2a ). This focus of association is the approximately 1Mb H1/H2 inversion polymorphism containing MAPT 15 .
We selected SNPs for stage 2 from the original set if they yielded P 1 < 10 −3 . We assessed 4,099 SNPs for association in 1,051 cases, most of which were living subjects clinically diagnosed with PSP (Supplementary Table 4) , and 3,560 control subjects, all of European ancestry. We also included 197 ancestry informative markers 16 to evaluate population substructure. Clinically diagnosed PSP 17 is rea sonably concordant with autopsy results 18 . We estimated the diag nostic misclassification rate as 12%, which has only a small impact on power (Online Methods).
We replicated all three loci associated in stage 1 by joint analysis ( Table 2 and Figs. 1 and 2) . A joint analysis revealed two new loci with joint P values (P J ) below the genomewide significance threshold. One of these loci was at 2p11.2 within EIF2AK3 (P J = 3.2 × 10 −13 ). Shown are SNPs significant at P < 5 × 10 −8 in the joint analysis. a MAF, minor allele frequency. b The OR is based on major allele. c rs242557 controlling for rs8070723. P 1 , stage 1 P; P 2 , stage 2 P; P J , joint P; STX6 encodes syntaxin 6; EIF2AK3 encodes eukaryotic translation initiation factor 2-α kinase 3; MOBP encodes myelin-associated oligodendrocyte basic protein; MAPT encodes microtubule associated protein tau. A summary of the function of each gene listed is in supplementary table 9. We determined associations using an additive genetic model. Exploratory analyses (results not shown) of PSP using dominant and recessive models did not produce new loci, although some of the associations in 17q21.31 were also consistent with these non-additive models. These less parsimonious models did not fit the data significantly better than the additive model. By evaluating 5,000 SNPs with the smallest P values in more complicated models involving main effects and interactions 38 we uncovered no noteworthy gene-gene interactions. There were additional SNPs in the regions for the above loci that were significant or strongly suggestive for association; however, these SNPs were no longer significant after controlling for the most significant SNP in the region (supplementary table 5). All loci significant in the joint analyses remained so after controlling for the MAPT inversion (supplementary table 10). l e t t e r s Another, rs12203592 (P J = 6.2 × 10 −15 ), at 6p25.3, highlighted IRF4, with a neighboring SNP in EXOC2, rs2493013 (P J = 6.0 × 10 −7 ); rs2493013 was significant after controlling for rs12203592 at P < 1 × 10 −3 (Supplementary Table 5 ). However, the allele frequencies for rs12203592 and rs2493013 in older controls were significantly differ ent from those of our controls (Supplementary Table 3 ). Curiously, the older control datasets were all significantly different from each other. Whereas rs12203592 alleles frequencies vary widely across Europe 19 , we could not ascribe these fluctuations amongst controls to either ancestry or genotyping artifacts. In the joint analysis, three other loci reached suggestive association (an intergenic region at 1q41, P J = 2.8 × 10 −7 ; BMS1, P J = 4.9 × 10 −7 ; SLCO1A2, P J = 1.9 × 10 −7 ; Supplementary Table 6 and Supplementary Fig. 2 ).
In the MAPT region, most of the PSPassociated SNPs mapped directly or closely to H1/H2, producing very small P values (for example, P 1 = 2.1 × 10 −51 and P J = 1.5 × 10 −116 for rs8070723). H1 confers risk, and 95% of PSP subject chromosomes have H1 as com pared to 77.5% of control chromosomes. In the stage 1 autopsy cases, the odds ratio (OR) is 5.5 (95% confidence interval (CI) 4.4-6.86, Table 2 ), which is stronger than the OR for the APOE ε3/ε4 genotype as a risk locus for Alzheimer's disease 20 . The OR for the stage 2 PSP samples was comparable to the stage 1 OR, which is evidence that the clinically and autopsy diagnosed cohorts are similar in composition.
If all of the risk from 17q21.31 were associated with H1/H2, con trolling for H1/H2 (using rs8070723 as a proxy) should be sufficient to make association at all other loci in this region nonsignificant. That was not the case; instead, certain SNPs remained associated, with the maximally associated SNP falling in MAPT (rs242557) ( 31 SNPs showed association after controlling for rs8070723 and rs242557 genotypes. rs242557 was previously identified as a key regulatory polymorphism influencing MAPT expression 21 . Note that rs242557 accounts for only part of the total risk associated with H1/H2 ( Table 2) .
The SNPs used to detect a genomewide association signal are not necessarily the riskcausing variants. For STX6 and EIF2AK3, there are nonsynonymous SNPs in close proximity to and highly corre lated with the top genomewide associated SNPs (Supplementary Table 7 ), making these coding changes candidates for the pathogenic change. To evaluate the possibility that some risk variants regulate gene expression, we analyzed the correlations between gene expres sion levels from two brain regions of 387 normal subjects and SNP genotypes for the regions listed in Table 2 . Two regions showed strong genotypeexpression associations (Fig. 3) . SNPs falling in or near MOBP have some effect on MOBP expression but are more strongly correlated with SLC25A38 expression, which is 70 kb from MOBP (Fig. 3a) . This effect on SLC25A38 is seen in the cerebellum but is weaker in the frontal cortex.
The second region showing a strong genotypeexpression corre lation is the MAPT inversion region. SNP alleles across the entire H1/H2 inversion and flanking regions show strong correlation with not only MAPT expression (P = 8.71 × 10 −28 for multiple SNPs) but also with ARL17A (P = 9.2 × 10 −22 ), PLEKHM1 (P = 1.0 × 10 −9 ) and LRRC37A4 (P = 2.2 × 10 −35 ) 12 . Note that although MAPT expression is correlated with SNPs across the entire inversion region, the SNPs influencing ARL17A are associated with a subset of regional SNPs and these are not identical to the SNPs affecting MAPT expression. Expression of CRHR1 and KIAA1267, genes that are in the inversion region and that flank MAPT, is not correlated with H1/H2 SNPs.
To distinguish between the effects on gene expression of the inver sion versus other independent effects, we controlled for H1/H2, as was l e t t e r s done for association with PSP ( Table 2) . After controlling for H1/H2, all significant geno typeexpression correlation for MAPT and LRRC37A4 disappeared (Fig. 3c) , showing that either the orientation of this region or a poly morphism that maps to H1/H2 determines MAPT expression. In contrast, controlling for H1/H2 had no effect on genotypeexpression correlations for ARL17A. Potential SNPs that affect expression (eSNPs) for ARL17A include rs242557 ( Table 2) , which is highly associated with PSP but which is more modestly corre lated with ARL17A expression, and rs8079215, which is highly cor related with ARL17A expression but not as strongly correlated with risk for PSP. Statistical modeling of these data produced the following conclusions: haplotypes involving H1 and rs242557 alleles predict a highly significant portion of the variability of ARL17A expression, however, essentially all of that variance can be explained by alleles at rs8079215, which are correlated with H1/H2 and rs242557 alleles; and that alleles at rs8079215 cannot predict risk for PSP independent of H1/H2 status even though they are excellent predictors of ARL17A expression. In sum, risk for PSP does not rise and fall with ARL17A expression. The global MAPT brain region expression analyzed here does not explain how rs242557 alleles confer risk to PSP. Yet this SNP or a correlated polymorphism is assumed to have a regulatory effect because there are no coding variants in MAPT brain isoforms that are candidate pathogenic variants. One possible explanation is that rs242557 alleles could affect alternative splicing without altering total MAPT expression levels 22, 23 . Because Alzheimer's disease and PSP are tauopathies, and because H1 is a shared risk factor for PSP and Parkinson's disease, we deter mined whether any confirmed Alzheimer's disease [24] [25] [26] [27] [28] or Parkinson's disease 29 loci also produced suggestive evidence for PSP association (Supplementary Table 8) . Besides the overlap between Parkinson's dis ease and PSP at MAPT, the single noteworthy result was from rs2075650 in TOMM40, which yielded P J = 1.28 × 10 −5 for association with PSP. TOMM40 is adjacent to APOE, and rs2075650 tags the Alzheimer's dis ease risk allele, ε4, in APOE. The effect in PSP is opposite of that seen in Alzheimer's disease: ε4 frequency is elevated in Alzheimer's disease and is diminished in PSP (for rs2075650, the estimated minor allele frequency (MAF) in cases was 0.11 versus a MAF of 0.15 in both our young and older controls; r 2 between rs2075650 and ε4 was 0.33).
Our work suggests a number of intriguing insights into PSP. One comes from EIF2AK3, a gene that encodes PERK, a component of the endoplasmic reticulum (ER) unfolded protein response (UPR). When excess unfolded proteins accumulate in the ER, PERK is acti vated and protein synthesis is inhibited, allowing the ER to clear misfolded proteins and return to homeostasis. The UPR is active in PSP 30 , Alzheimer's disease 31 and Parkinson's disease 32 . In PSP, activated PERK is in neurons, oligodendrocytes and astrocytes 30 . In Alzheimer's disease, activated UPR components are found in pre tangle neurons in a number of brain regions 31 . In Parkinson's disease, UPR activation occurs in neuromelanincontaining dopaminergic neurons in the substantia nigra 32 . How the UPR contributes to PSP pathogenesis is unclear because the primary misfolded protein in PSP, tau, is not a secreted protein and thus is not expected to traffic through the ER.
The PSP susceptibility gene STX6 encodes syntaxin 6 (STX6), a SNAREclass protein. SNARE proteins are part of the cellular machin ery that catalyzes the fusion of vesicles with membranes 33 . STX6 is localized to the transGolgi network and endosomal structures 34 . Because our work implicates ER stress in PSP pathogenesis, genetic variation at STX6 could influence movement of misfolded proteins from the ER to lysosomes through the endosomal system.
MOBP (P J = 1 × 10 −16 ), like MBP, the myelin basic protein gene, encodes a protein (MOBP) that is produced by oligodendrocytes and is present in the major dense line of central nervous system myelin. MOBP is highly expressed in the white matter of the medulla, pons, cerebellum and midbrain 35 , regions affected in PSP. Our findings sug gest that myelin dysfunction or oligodendrocyte misfunction contrib utes to PSP pathogenesis.
Our work generates a testable translational hypothesis based on the results for EIK2AK3. Our work suggests that perturbation of the UPR can influence PSP risk, and that the UPR is not just a downstream consequence of neurodegeneration. Thus pharmacologic modulation of the UPR is a potential therapeutic strategy for PSP 36,37 . The data presented here are independent samples from those used previously 12 .
l e t t e r s
METhodS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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We thank the subjects and their families that participated in this study. Table 1 ). The neuropathological diagnosis was made according to the NINDS diag nostic criteria 38, 39 . DNA was extracted from brain tissue from cases who had consented for brain donation.
The stage 2 sample consisted of 1,244 individuals diagnosed with PSP and 3,654 control subjects, none of whom were included in stage 1. The majority of cases were clinically diagnosed (1,113 cases), although some were auto psied (131 cases). Clinical cases were recruited through specialized movement disorder hospitals and clinics and referrals from neurologists (Supplementary Table 4 ). All cases fulfilled the clinical diagnosis of possible or probable PSP 17 . The diagnostic assessments involved a review of the individual's full medical history, neurological examinations and mental status evaluations. The demo graphic data included gender, age at onset of motor symptoms, disease dura tion and final clinical diagnosis. Informed consent was obtained for blood collection and genetic analysis. The University of Pennsylvania assembled all DNA samples identified for the study.
Controls for stage 1 and 2 were young subjects recruited from the Children's Hospital of Philadelphia (CHOP) Health Care Network by CHOP clinicians and nursing staff. Written informed consent was obtained from all subjects. The stage 1 cohort was largely of European ancestry (89.5%), whereas all of the stage 2 controls were of European ancestry. Females comprised 47.7% and 47.0% of the stage 1 and 2 samples, respectively; the mean ages for the stage 1 and 2 cohorts were 7.8 years and 8.8 years, respectively. The advantage of using these controls is that all were genotyped at the same center using the same protocols as the cases. Although the controls were not selected for an absence of neurodegenerative disease, the low population frequency of PSP ensures a negligible number of controls will get PSP later in life. The disadvan tage of young controls is that some loci could also have a positive or negative impact on survival. To diminish this disadvantage, for SNPs significantly or suggestively associated with PSP, we compared the control allele frequencies of our younger samples with those from a set of older controls (N = 3,816) obtained from the NIH repository Database for Genotypes and Phenotypes. Only SNPs for which there was no difference between young and old frequen cies were reported in Table 2 .
Genotyping. Stage 1 cases were genotyped by the Center for Applied Genomics at CHOP using Human 660WQuad Infinium BeadChips. Control samples were genotyped using the Illumina Human HapMap550 Infinium BeadChip. Stage 2 cases were genotyped for 5,283 SNPs using Infinium HD iSelect Custom BeadChip, most of which were identified by CHOP or at the University of Pittsburgh at stage 1 as SNPs showing association by the logadditive model at P ≤ 0.001. Ancestry informative markers, or AIMs, were also included. Stage 2 controls were selected from a larger CHOP control dataset to match cases in terms of genetic ancestry.
Quality control. Quality control procedures were performed at the individual and then at the SNP level. At the individual level, gender miscalls based on chromosome X and Y genotypes, duplicate samples and highly related sam ples were excluded. At the SNP level, a genotype completion rate of ≥98% was required. HardyWeinberg equilibrium (HWE) was evaluated in samples of European ancestry, and SNPs failing HWE were excluded (P < 1 × 10 −4 ). To control potential confounding caused by variation in genetic ancestry, cases and controls were matched for ancestry based on genetic data using methods previously described 40, 41 . All quality control and subsequent association analy ses were performed independently at CHOP by P.M.S. and at the University of Pittsburgh by N.M.M and L.K. Results were then compared for agreement. The analytic methods and results described are those used at the University of Pittsburgh unless otherwise noted.
For stage 1, there were three gender inconsistencies (one case and two con trols), 32 samples were duplicates (all cases), and 12 samples had genotyping completion rate <98%. These samples were eliminated. For SNPs, 4,222 were monomorphic, had uncalled genotypes or had genotyping completion rate <98%. Ancestry for cases and controls was determined using 6,490 SNPs with a call
